- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02106585
Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects
October 3, 2014 updated by: Akros Pharma Inc.
Phase 1, Randomized, Single-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of JTT-251 Single Oral Doses in Healthy Subjects (Part Ia) and in Type 2 Diabetic Subjects (Part Ib) and Randomized, Open-label, Crossover Study Evaluating Effect of Food on PK in Healthy Subjects (Part II)
The purpose of this study is to evaluate the safety, tolerability, and PK (Pharmacokinetics) of single oral doses of JTT-251 in healthy and type 2 diabetes mellitus subjects and to evaluate the effect of food on the PK of JTT-251 in healthy subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
94
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Orlando, Florida, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Healthy Subject Cohorts:
- Healthy male or female subjects
- Body Mass Index (BMI) between 19.0 and 31.0 kg/m2 (inclusive)
Type 2 Diabetic Subject Cohorts:
- Male or female Type 2 diabetic subjects diagnosed for at least 3 months
- BMI between 25 and 40 kg/m2 (inclusive)
- Have a glycosylated hemoglobin (HbA1c) of >6.5% to ≤10.9% (inclusive) if treatment naïve with respect to hypoglycemic agents OR >6.5% to ≤10.0% (inclusive) if treated with metformin
Exclusion Criteria:
Healthy Subject Cohorts:
- Known clinically relevant history or presence of significant respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, metabolic, and dermatological or connective tissue disease
- Subjects with a systolic blood pressure >150 mmHg and/or diastolic blood pressure >90 mmHg
Type 2 Diabetic Subject Cohorts:
- Subjects with a known medical history or presence of type 1 diabetes mellitus
- Subjects with known medical history of acute metabolic diabetic complications
- Subjects with uncontrolled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >95 mmHg with documented ongoing treatment)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Dose 1 JTT-251 or Placebo
Tablets, single dose in fed condition
|
Subjects will receive JTT-251 or Placebo
|
|
EXPERIMENTAL: Dose 2 JTT-251 or Placebo
Tablets, single dose in fed condition
|
Subjects will receive JTT-251 or Placebo
|
|
EXPERIMENTAL: Dose 3 JTT-251 or Placebo
Tablets, single dose in fed condition
|
Subjects will receive JTT-251 or Placebo
|
|
EXPERIMENTAL: Dose 4 JTT-251 or Placebo
Tablets, single dose in fed condition
|
Subjects will receive JTT-251 or Placebo
|
|
EXPERIMENTAL: Dose 5 JTT-251 or Placebo
Tablets, single dose in fed condition
|
Subjects will receive JTT-251 or Placebo
|
|
EXPERIMENTAL: Dose 6 JTT-251 or Placebo
Tablets, single dose in fed condition
|
Subjects will receive JTT-251 or Placebo
|
|
EXPERIMENTAL: Dose 7 JTT-251 or Placebo
Tablets, single dose in fed condition
|
Subjects will receive JTT-251 or Placebo
|
|
EXPERIMENTAL: Dose 8 JTT-251 or Placebo
Tablets, single dose in fed condition
|
Subjects will receive JTT-251 or Placebo
|
|
EXPERIMENTAL: Dose 9 JTT-251 or Placebo
Tablets, single dose in fasted or fed condition followed by a single dose in the alternate fed or fasted condition
|
Subjects will receive JTT-251 or Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of subjects with adverse events
Time Frame: 1 week
|
1 week
|
|
Vital signs and 12 lead ECGs
Time Frame: 1 week
|
1 week
|
|
Cmax (maximum concentration)
Time Frame: 1 week
|
1 week
|
|
t1/2 (elimination half-life)
Time Frame: 1 week
|
1 week
|
|
AUC (area under the concentration-time curve)
Time Frame: 1 week
|
1 week
|
|
fe(total) (fraction of systemically available drug excreted into the urine over entire collection interval)
Time Frame: 1 week
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (ACTUAL)
August 1, 2014
Study Completion (ACTUAL)
August 1, 2014
Study Registration Dates
First Submitted
April 4, 2014
First Submitted That Met QC Criteria
April 4, 2014
First Posted (ESTIMATE)
April 8, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
October 7, 2014
Last Update Submitted That Met QC Criteria
October 3, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- AT251-U-13-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.